BioSpace News Archive

Xenon Pharmaceuticals Inc. announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL.

Sight Sciences, Inc. announced the results as published in the journal Clinical Ophthalmology of a new analysis of the ROMEO study data.

CorMedix Inc. today announced that it has entered into a multi-year commercial supply contract with a top tier midsized dialysis provider for the supply of DefenCath ® (taurolidine and heparin).

PreciseDx today announced its attendance and participation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA.

IceCure Medical Ltd. today reported financial results as of and for the three months ended March 31, 2024.

Integrated Biosciences today announced they have joined Illumina Ventures Labs to integrate the company’s drug discovery engine with Illumina sequencing.

Butterfly Network, Inc. today announced that Joseph DeVivo, President, Chief Executive Officer and Chairman will present and host one-on-one investor meetings at the Goldman Sachs 45th Annual Global Healthcare Conference.

Jaguar Health, Inc. today announced that the results of a third-party, investigator-initiated study of crofelemer, Napo’s novel plant-based prescription drug, show that twice daily oral administration of crofelemer led to a statistically meaningful reduction of abdominal pain and discomfort and improved stool consistency in functional diarrhea patients.

Aprea Therapeutics, Inc. today announced that the Safety Review Committee (SRC) overseeing the ongoing ABOYA-119 clinical trial has determined that dosing of patients with ATRN-119 at 800 mg once daily (Cohort 6) can commence and that Cohort 6 is open for enrollment.